Suppliers / Daxin Pharmaceuticals

Daxin Pharmaceuticals

China 5 employees Updated 9 July 2026

Daxin Pharmaceuticals is an API manufacturer based in China. Customs aggregates show $103K of exports covering 16 molecules to 1 destination in 2023.

0
active US DMFs
0
valid CEPs
0
registered plants
0
filings across 0 regulators

What they file, and where

Molecule Regulators Docs
Tobramycin SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Tobramycin API

Scale

Year Revenue Exports Destinations
2023 Not reported $103K 1
2022 Not reported $174K 1

Export figures are customs aggregates. We do not publish the identity of any buyer.

Questions about Daxin Pharmaceuticals

What does Daxin Pharmaceuticals make?
1 molecule is on record against Daxin Pharmaceuticals, including Tobramycin. Each links through to that molecule's full manufacturer list.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Daxin Pharmaceuticals comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Comparable suppliers

Livzon Group Fuzhou Fuxing Pharmaceutical shares 1 molecule Xellia Pharmaceuticals shares 1 molecule Chongqing Daxin Pharmaceutical shares 1 molecule Livzon New North River Pharmaceutical shares 1 molecule Minh shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
Customs aggregates
Export values, molecule and destination counts